Quarterly report · Q3
2370.TEDINET S100P0C7
Period2021-10-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥470m | 2021-10-01 → 2022-06-30 | Standalone | Net sales |
| Revenue | ¥683m | 2020-10-01 → 2021-09-30 | Standalone | Net sales (5-year summary) |
| Revenue | ¥512m | 2020-10-01 → 2021-06-30 | Standalone | Net sales |
| Operating income | −¥988m | 2021-10-01 → 2022-06-30 | Standalone | Operating income |
| Operating income | −¥792m | 2020-10-01 → 2021-06-30 | Standalone | Operating income |
| Ordinary income | −¥984m | 2021-10-01 → 2022-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥871m | 2020-10-01 → 2021-09-30 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥577m | 2020-10-01 → 2021-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥985m | 2021-10-01 → 2022-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥545m | 2020-10-01 → 2021-06-30 | Standalone | Income before income taxes |
| Net income | −¥989m | 2021-10-01 → 2022-06-30 | Standalone | Profit loss |
| Net income | −¥843m | 2020-10-01 → 2021-09-30 | Standalone | Net income loss (5-year summary) |
| Net income | −¥549m | 2020-10-01 → 2021-06-30 | Standalone | Profit loss |
| Total assets | ¥6.3bn | at 2022-06-30 | Standalone | Assets |
| Total assets | ¥5.4bn | at 2021-09-30 | Standalone | Assets |
| Total assets | ¥5.7bn | at 2021-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥539m | at 2022-06-30 | Standalone | Liabilities |
| Total liabilities | ¥475m | at 2021-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥5.7bn | at 2022-06-30 | Standalone | Net assets |
| Net assets / equity | ¥4.9bn | at 2021-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.2bn | at 2021-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.8bn | at 2022-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.1bn | at 2021-09-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥-5.11 | 2021-10-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.5 | 2022-04-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.88 | 2020-10-01 → 2021-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.21 | 2020-10-01 → 2021-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.22 | 2021-04-01 → 2021-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 91.4% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.8% | at 2021-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.2% | at 2021-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 211,730,423 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 178,750,423 | at 2021-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 177,730,423 | at 2021-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-06-30 | −¥386m |
| jpcrp040300-q3r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue | 2021-10-01 → 2022-06-30 | ¥194,000 |
| jpcrp040300-q3r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue external | 2021-10-01 → 2022-06-30 | ¥194,000 |
| jpcrp040300-q3r_E05351-000Cellular And Tissue Based Product Businessreportable segment | segment profit | 2021-10-01 → 2022-06-30 | −¥425m |
| jpcrp040300-q3r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue | 2021-10-01 → 2022-06-30 | ¥470m |
| jpcrp040300-q3r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue external | 2021-10-01 → 2022-06-30 | ¥470m |
| jpcrp040300-q3r_E05351-000Contract Cell Manufacturing Businessreportable segment | segment profit | 2021-10-01 → 2022-06-30 | −¥178m |
| —segment total | revenue | 2021-10-01 → 2022-06-30 | ¥470m |
| —segment total | revenue external | 2021-10-01 → 2022-06-30 | ¥470m |
| —segment total | segment profit | 2021-10-01 → 2022-06-30 | −¥603m |
| Reconciling Itemsreconciling | segment profit | 2020-10-01 → 2021-06-30 | −¥385m |
| jpcrp040300-q3r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue | 2020-10-01 → 2021-06-30 | ¥143,000 |
| jpcrp040300-q3r_E05351-000Cellular And Tissue Based Product Businessreportable segment | revenue external | 2020-10-01 → 2021-06-30 | ¥143,000 |
| jpcrp040300-q3r_E05351-000Cellular And Tissue Based Product Businessreportable segment | segment profit | 2020-10-01 → 2021-06-30 | −¥319m |
| jpcrp040300-q3r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue | 2020-10-01 → 2021-06-30 | ¥512m |
| jpcrp040300-q3r_E05351-000Contract Cell Manufacturing Businessreportable segment | revenue external | 2020-10-01 → 2021-06-30 | ¥512m |
| jpcrp040300-q3r_E05351-000Contract Cell Manufacturing Businessreportable segment | segment profit | 2020-10-01 → 2021-06-30 | −¥88m |
| —segment total | revenue | 2020-10-01 → 2021-06-30 | ¥512m |
| —segment total | revenue external | 2020-10-01 → 2021-06-30 | ¥512m |
| —segment total | segment profit | 2020-10-01 → 2021-06-30 | −¥407m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 318
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | 512112000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 143000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 512256000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember | 512256000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | -88030000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | -319435000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | -407466000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -384564000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember | -792031000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | 469590000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 194000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 469785000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember | 469785000 | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | 469590000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 194000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 469785000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember | 469785000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000ContractCellManufacturingBusinessReportableSegmentsMember | -177589000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | -424998000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | -602587000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -385818000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember | -988406000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-12 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第27期第３四半期（自 2022年４月１日 至 2022年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社メディネット | |
| Company name in english cover page | FilingDateInstant | MEDINET Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 久布白 兼直 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都品川区勝島一丁目５番21号（同所は登記上の本店所在地であり、実際の業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都大田区平和島六丁目１番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)（０３）６６３１－１２０１（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営管理部長 落合 雅三 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05351 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 23700 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社メディネット |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |